Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grapiprant - AskAt

Next Previous
Drug Profile

Grapiprant - AskAt

Alternative Names: 423; AAT-007; ARY 007; CJ-023; CJ-023,423; CJ-23423; IK 007; MR-10A7; NB-001 - Ningbo NewBay Medical Technology; RMX-1002; RQ-00000007; RQ-07; RQ-7

Latest Information Update: 30 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AskAt; HaiHe Biopharma; Ikena Oncology; M. D. Anderson Cancer Center; Ningbo NewBay Medical Technology
  • Class Analgesics; Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Benzene derivatives; Imidazoles; Pyridines; Small molecules; Sulfonamides; Sulfonylureas
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cancer pain; Neuropathic pain
  • Phase II Pain
  • Phase I/II Breast cancer; Non-small cell lung cancer; Solid tumours
  • Discontinued Colorectal cancer; Hypersensitivity; Inflammation

Most Recent Events

  • 30 Sep 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy) (PO) Prior to September 2026 (Ningbo NewBay Medical Technology pipeline, September 2026)
  • 01 Feb 2026 Pharmacodynamics data from a preclinical study in Cancer released by ASKAT
  • 18 Sep 2025 Phase-I observational clinical development in Solid tumours (Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater) is underway in China (PO) (ChiCTR1900026031) (Askat pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top